Cathy Maes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/446110/publications.pdf

Version: 2024-02-01

		1040056	
10	457	9	10
papers	citations	h-index	g-index
10	10	10	822
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Priming with ASO3A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open non-randomised extension of a double-blind randomised primary study. Vaccine, 2010, 28, 849-857.	3.8	127
2	Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes. PLoS ONE, 2013, 8, e55438.	2.5	69
3	A randomized, observer-blind Phase Ib study to identify formulations and vaccine schedules of a trivalent Group B Streptococcus vaccine for use in non-pregnant and pregnant women. Vaccine, 2016, 34, 1786-1791.	3.8	60
4	Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: A phase I/II randomized clinical study. Vaccine, 2014, 32, 6838-6846.	3.8	56
5	Effect on Cellular and Humoral Immune Responses of the AS03 Adjuvant System in an A/H1N1/2009 Influenza Virus Vaccine Administered to Adults during Two Randomized Controlled Trials. Vaccine Journal, 2011, 18, 835-843.	3.1	47
6	Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study. Vaccine, 2019, 37, 2694-2703.	3.8	30
7	Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥50 years of age: Results from a phase III, randomized, non-inferiority trial. Vaccine, 2017, 35, 6321-6328.	3.8	25
8	Randomized Trial of the Immunogenicity and Safety of the Hepatitis B Vaccine Given in an Accelerated Schedule Coadministered with the Human Papillomavirus Type 16/18 ASO4-Adjuvanted Cervical Cancer Vaccine. Vaccine Journal, 2011, 18, 1510-1518.	3.1	18
9	Safety and Immunogenicity of a Second Dose of an Investigational Maternal Trivalent Group B Streptococcus Vaccine in Nonpregnant Women 4–6 Years After a First Dose: Results From a Phase 2 Trial. Clinical Infectious Diseases, 2020, 70, 2570-2579.	5 . 8	18
10	Pregnancy has a minimal impact on the acute transcriptional signature to vaccination. Npj Vaccines, 2020, 5, 29.	6.0	7